1
|
Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia.
|
Blood
|
2007
|
2.15
|
2
|
Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method.
|
Nucleic Acids Res
|
2007
|
1.62
|
3
|
RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia.
|
Blood
|
2012
|
1.33
|
4
|
Curcumin is a potent DNA hypomethylation agent.
|
Bioorg Med Chem Lett
|
2008
|
1.31
|
5
|
A LC-MS/MS method for the analysis of intracellular nucleoside triphosphate levels.
|
Pharm Res
|
2009
|
1.07
|
6
|
Curcumin down-regulates DNA methyltransferase 1 and plays an anti-leukemic role in acute myeloid leukemia.
|
PLoS One
|
2013
|
1.05
|
7
|
Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.
|
Clin Cancer Res
|
2008
|
1.05
|
8
|
Triphala and its active constituent chebulinic acid are natural inhibitors of vascular endothelial growth factor-a mediated angiogenesis.
|
PLoS One
|
2012
|
1.04
|
9
|
Modulation of DNA methylation by a sesquiterpene lactone parthenolide.
|
J Pharmacol Exp Ther
|
2009
|
0.99
|
10
|
Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation.
|
Br J Haematol
|
2010
|
0.99
|
11
|
Quantification of regional DNA methylation by liquid chromatography/tandem mass spectrometry.
|
Anal Biochem
|
2009
|
0.90
|
12
|
Serum levels of intravitreal bevacizumab after vitrectomy, lensectomy and non-surgical controls.
|
Curr Eye Res
|
2013
|
0.89
|
13
|
Synthetic microRNA cassette dosing: pharmacokinetics, tissue distribution and bioactivity.
|
Mol Pharm
|
2012
|
0.87
|
14
|
Sensitive detection of prion protein in human urine.
|
Exp Biol Med (Maywood)
|
2005
|
0.86
|
15
|
Reactivation of RASSF1A in breast cancer cells by curcumin.
|
Nutr Cancer
|
2012
|
0.83
|
16
|
Metabolism of GTI-2040, a phosphorothioate oligonucleotide antisense, using ion-pair reversed phase high performance liquid chromatography (HPLC) coupled with electrospray ion-trap mass spectrometry.
|
AAPS J
|
2006
|
0.83
|
17
|
A novel ultrasensitive hybridization-based ELISA method for 2-methoxyphosphorothiolate microRNAs and its in vitro and in vivo application.
|
AAPS J
|
2010
|
0.83
|
18
|
Biochemical modulation of aracytidine (Ara-C) effects by GTI-2040, a ribonucleotide reductase inhibitor, in K562 human leukemia cells.
|
AAPS J
|
2010
|
0.80
|
19
|
A liquid chromatography/atmospheric pressure ionization tandem mass spectrometry quantitation method for nevirapine and its two oxidative metabolites, 2-hydroxynevirapine and nevirapine 4-carboxylic acid, and pharmacokinetics in baboons.
|
Rapid Commun Mass Spectrom
|
2007
|
0.79
|
20
|
Determination of cellular uptake and intracellular levels of Cenersen (Aezea(®), EL625), a p53 antisense oligonucleotide in acute myeloid leukemia cells.
|
J Pharm Biomed Anal
|
2012
|
0.76
|
21
|
Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia.
|
Leuk Lymphoma
|
2013
|
0.76
|
22
|
Enzyme kinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase.
|
Drug Metab Dispos
|
2008
|
0.76
|